### KID-3 and KID-4

**Internal request:**
Panel comment to reassess the category designations for the regimens for both clear cell and non-clear cell RCC with predominant sarcomatoid features:
- gemcitabine + doxorubicin
- gemcitabine + capecitabine.

**Panel Discussion:**
The panel discussion regarding the regimens for both clear cell and non-clear cell RCC with predominant sarcomatoid features resulted in:
- A change in the category for chemotherapy as an option from a category 3 to a category 2B
- The removal of gemcitabine + capecitabine.

<table>
<thead>
<tr>
<th>Vote</th>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>13</td>
<td>4</td>
<td>0</td>
</tr>
</tbody>
</table>

**References:**

### KID-4

**Internal request:**
Panel comment to add the regimen, cisplatin + sunitinib, for both clear cell and non-clear cell RCC with predominant sarcomatoid features.

**Panel Discussion:**
Based on discussion and the noted reference, the panel consensus was to include gemcitabine + sunitinib as an option for both clear cell and non-clear cell RCC with predominant sarcomatoid features.

<table>
<thead>
<tr>
<th>Vote</th>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>16</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**References:**